诺孕酪与乙炔雌二醇的混合物 | 79871-54-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 诺孕酪与乙炔雌二醇的混合物
• 英文名称: Tri-sprintec
• 英文别名: [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 79871-54-8
• 化学式: C43H55NO5
• 分子量: 665.9
• InChiKey: GYMWQLRSSDFGEQ-ADRAWKNSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.33
• 重原子数：
  49
• 可旋转键数：
  5
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  99.4
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  炔雌醇 、 norgestimate 、 以Adjust Jet mill to produce particle size of 5-10 μm的产率得到诺孕酪与乙炔雌二醇的混合物
  参考文献：
  名称：

  Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals

  摘要：

  本发明涉及一种基底涂层，用于静电沉积干粉药物，用于制造药物剂量形式，包括微粒化聚乙二醇（PEG），其分子量在1,000至20,000范围内，并具有1-100μm的粒径。本发明还涉及具有这种基底涂层的药物组合物，以及制造这种药物组合物的过程。本发明还涉及将药物的负电荷反转的技术，使其可以静电沉积在带负电荷的基底上。

  公开号：

  US20020102308A1

文献信息

• NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
  申请人：Human Genome Sciences, Inc.

  公开号：EP1254151A1

  公开（公告）日：2002-11-06
• METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND SEX STEROIDS AS A COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF DISMENORRHEA
  申请人：Pharmacia Corporation

  公开号：EP1363669A2

  公开（公告）日：2003-11-26
• HUMAN SECRETED PROTEINS
  申请人：Human Genome Sciences, Inc.

  公开号：EP1408759A2

  公开（公告）日：2004-04-21
• EP1408759A4
  申请人：——

  公开号：EP1408759A4

  公开（公告）日：2005-04-06
• [EN] NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES<br/>[FR] ACIDES NUCLEIQUES, PROTEINES, ET ANTICORPS
  申请人：HUMAN GENOME SCIENCES INC

  公开号：WO2001055163A1

  公开（公告）日：2001-08-02

  The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.